Biortus Delivering hERG Protein and Cryo-EM Structures

As part of the drug safety assessment practice, ion channels are one of the key family proteins under tight scrutiny with almost every drug candidate. Unfortunately, as of now the effect of drug candi

26

2022

/

04

Biortus Delivering ABCB10 Protein and Cryo-EM Structures

A member of ATP-binding cassette (ABC) transporter family located in the inner membrane of mitochondria, ABCB10 in the liver functions as a transporter of liver biliverdin, the reduction product of bilirubin (Fig. 1).

26

2022

/

04

Installed Krios G4 Boosts Productivity at Biortus CryoEM Center

Reporting from Wuxi, the long anticipated Titan Krios G4, the first of its kind in China, is now installed and operational at the Biortus CryoEM Center.

03

2021

/

05

Biortus Announces Round A Financing and Launches Global Cryo-EM Innovation Center

Wuxi Biortus Biosciences Co. Ltd. (“Biortus”), a global leader in structural biology service for drug discovery, recently closed round A financing with US$15 million investment led by Bayland Capital, and the fund will be used to establish a global cryo-EM innovation center.

12

2020

/

10

MicroED Service at Biortus Facilitates Drug Development

Microcrystal electron diffraction (MicroED) is a new crystal structure determination technique for small molecules. It obtains diffraction patterns of small molecule microcrystal from an electron microscope, and resolves the atomic-resolution structure (better than 1.0A) with the traditional crystallography approach. The emergence of MicroED technology has raised great interest within the pharmaceutical research and development community. This technology holds great prospects of identifying the crystal form of drug substance, determining the structure of a natural product, and analyzing impurity in CMC process.

14

2020

/

09

High-Quality Full-Length LRRK2 Ready for Structure-Based Drug Discovery

Leucine-rich repeat kinase 2 (LRRK2) is implicated in the pathogenesis of Parkinson’s disease (PD), which is the second most common neurodegenerative movement disorder and affects 1–2% of all people above the age of 65. Unfortunately, there has been no effective cure for PD yet. LRRK2 is one of the most promising therapeutic targets for drug therapy in PD and several LRRK2 inhibitors are currently in clinical trials.

05

2020

/

06

< 123 >